ReviewFunctional & integrative genomics2025
LSINCT5: a pivotal oncogenic long non-coding RNA in cancers.
Review in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- iLDA-SGCN: Identifying Associations Between Age-Related Diseases and Long Non-Coding RNAs Using Dual Graph Convolutional Networks.Aging cell · 2026Article
- Comparative roles between Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1) in lung and colorectal cancer: insights into tumorigenesis and metastasis.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Long stress-induced non-coding transcript 5 (LSINCT5) is a long non-coding RNA (lncRNA) that has been demonstrated to exhibit oncogenic properties as its upregulation was found to be commonly associated with malignant clinicopathological features in various cancers. Numerous studies have reported that LSINCT5 overexpression may promote cancer progression by regulating the expression of genes that modulate important aspects of cell activity and by interfering with signalling pathways via precise mechanisms such as microRNA (miRNA) sponging, protein interactions, as well as acting as a downstream target of transcription factors. Eventually, these processes stimulate malignant behaviour such as proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT). Research suggests LSINCT5 could be a useful biomarker and therapeutic target. However, understanding their complex nature and impact on physiological processes is crucial for determining their oncogenic properties and potential use in therapy. This review focuses on LSINCT5's biological functions, expression patterns, oncogenic roles, and molecular mechanisms in cancers. We further highlight the potential of LSINCT5 as a biomarker for early diagnosis and prognosis, as well as a therapeutic target in cancer therapy.
Indexed as
Identifiers
40455308What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.